Seeking efficiency in executive compensation benchmarking?

Unlock Efficiency in Executive Compensation Benchmarking with CompAnalyst Executive

CompAnalyst Executive

The charts on this page feature a breakdown of the total annual pay for the top executives at ICOSAVAX INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ICOSAVAX INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ICOSAVAX INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Adam Simpson
Chief Executive Officer
Total Cash $846,800 Equity $6,050,441 Other $9,150 Total Compensation $6,906,391
Cassia Cearley
Chief Business Officer
Total Cash $623,000 Equity $1,750,390 Other $9,150 Total Compensation $2,382,540
Niranjan Kanesa-thasan
Chief Medical Officer
Total Cash $632,400 Equity $1,582,442 Other $9,150 Total Compensation $2,223,992
For its 2022 fiscal year, ICOSAVAX INC, listed the following board members on its annual proxy statement to the SEC.
Ann Veneman Total Cash $184,707
Elisha Gould, III Total Cash $21,863
Heidi Kunz Total Cash $196,520
James Wassil Total Cash $307,587
John W. Shiver, Ph.D. Total Cash $710,774
Mark McDade Total Cash $234,020
Peter Kolchinsky, Ph.D. Total Cash $184,520

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.